BIO-CAT Joins Lallemand, Expanding US Enzyme and Microbial Production Capacity

Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes and Microbials, combining 2 companies with overlapping expertise in fermentation and microbial technology used across dietary supplements, animal nutrition, and food applications.¹

For manufacturers sourcing enzyme and probiotic ingredients, the deal adds to a broader pattern of consolidation among ingredient suppliers seeking to expand manufacturing capacity rather than compete solely on formulation science alone.

"When my father, Ed Schuler, and I founded BIO-CAT in 1988, we built the company around family values, science, integrity, and lasting relationships," said Chris Schuler, BIO-CAT's leadership. "Finding a partner with shared values was just as important as finding one with complementary technologies. Lallemand's family-owned heritage, long-term vision, and commitment to its people and customers made this a natural fit, and we're excited about what we'll accomplish together."

What Does This Acquisition Actually Combine?

BIO-CAT has operated since 1988 as a supplier of enzyme and microbial-based ingredients, offering custom formulation, blending, and fermentation services alongside branded ingredient lines for dietary supplements, food and beverage, and animal nutrition markets.

Lallemand, a Canadian company built around yeast and bacteria fermentation technology, brings a broader existing footprint across probiotics, food ingredients, and industrial fermentation. Antoine Chagnon, Lallemand’s CEO, framed the acquisition around geographic and capacity expansion rather than a shift in product focus: "The acquisition will reinforce our presence in the dietary food supplement and health ingredient markets, and increase our production footprint and capacity in the USA. This, in turn, should better enable us to meet the requirements of our existing and new customers across the global animal nutrition, agriculture and food industries."

Why Does Manufacturing Capacity Matter in the Enzyme and Probiotic Ingredient Category Right Now?

Demand for digestive enzyme supplements has continued to grow, with one market analysis projecting the global digestive enzyme supplement category to expand from $12.53 billion in 2026 to $20.48 billion by 2034.²

That growth has coincided with increasing formulation complexity: enzyme activity can degrade under heat, moisture, and pH exposure, which has made stability and manufacturing precision a more prominent differentiator as brands move beyond single-enzyme capsules into multi-enzyme systems, gummies, and other newer delivery formats.² For a supplier like BIO-CAT, aligning with a larger fermentation-focused parent company potentially addresses a scaling challenge common across the ingredient supply industry: growing customer demand for enzyme and microbial ingredients often outpaces a mid-sized supplier's own capital capacity to expand production independently.

What Should Manufacturers Expect From This Kind of Consolidation?

Acquisitions that combine a specialized ingredient supplier with a larger parent company typically preserve existing product lines and customer relationships in the near term, since disrupting an established formulation or supply agreement carries its own commercial risk.

Whether BIO-CAT's branded ingredient lines, including its OPTIZIOME, OPTIBIOME, and OPTIFEED product families, remain under their existing names or get folded into Lallemand's broader portfolio naming conventions is not addressed in the companies' announcement.

Manufacturers currently sourcing from BIO-CAT should expect continuity in existing supply relationships in the short term, though longer-term integration decisions, including potential consolidation of manufacturing sites or formulation support teams, are not yet detailed publicly.

What Remains Unclear About This Deal?

The announcement does not disclose the financial terms of the transaction, specific production volume or capacity figures, or a timeline for when expanded US manufacturing capacity will come online. It also does not specify whether BIO-CAT's leadership, including Chris Schuler, will remain in an operating role post-acquisition, or how the two companies' existing custom formulation and research and development services will be integrated.

As with most privately negotiated ingredient supplier acquisitions, additional operational detail is likely to emerge as integration proceeds.

References

1. BIO-CAT joins the Lallemand family. BIO-CAT. August 4, 2026. Accessed August 6, 2026. https://www.bio-cat.com/2026/08/04/bio-cat-joins-the-lallemand-family/

2. Digestive enzyme supplements market size, share, & industry analysis, 2026-2034. Fortune Business Insights. July 20, 2026. Accessed Augus t6, 2026. https://www.fortunebusinessinsights.com/digestive-enzyme-supplements-market-115483